Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Tuesday that its second quarter revenues rose 168 percent year over year, thanks largely to strong growth in its melanoma and uveal melanoma test volumes.

For the three months ended June 30, the skin cancer test developer reported total revenues of $10.7 million, up from $4.0 million during the same period a year earlier, and beating the average Wall Street analyst estimate of $7.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.